Enzalutamide Drugs Market: Opportunity by 2034 | In-Depth Report

Enzalutamide Drugs by Type (Tablets, Capsules), by Application (Hospital and Clinic, Retail Pharmacies, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 142

Forecast Period: 2026 - 2033

Market Size: $7.2 million

CAGR: 15.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 142

Forecast Period: 2026 - 2033

Market Size: $7.2 million

CAGR: 15.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Enzalutamide Drugs Market Overview

Enzalutamide drugs—next-generation oral androgen-receptor inhibitors—are the backbone of treatment for metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic CRPC. Against a backdrop of rising prostate-cancer incidence and the global shift toward value-based oncology, the Enzalutamide Drugs market size is forecast to advance from US$6.4 billion in 2025 to US$11.3 billion by 2033, translating to a 9.1% CAGR over the 2026-2033 market forecast. This robust growth outlook is underpinned by label expansions into earlier lines of therapy, rapid uptake of high-dose formulations, and the accelerating transition from branded Xtandi to cost-efficient generics in Europe and Latin America—collectively driving industry expansion and widening patient access.

Loading chart…

Three macro forces are reshaping competitive dynamics: (1) regulatory pressure for oncology value assessments triggering price-volume agreements across the EU-5; (2) supply-chain localization as Indian and Chinese API producers secure 60%+ share of enzalutamide intermediates, compressing COGS for generics; and (3) patient-centric demand for convenient 160-mg high-dose tablets that cut pill burden by half, now capturing >30% of new Rx in the U.S. North America remains the largest region (≈55% share), while Asia-Pacific is the fastest-expanding territory (12% CAGR) on the back of China’s National Reimbursement Drug List inclusion and India’s accelerating generic penetration.

Report Overview

Report Attribute	Details
Market size value in 2025	7.20 million
Revenue forecast in 2033	22.65 million
Growth rate	CAGR of 15.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Astellas Pharma; Pfizer; Intas Pharmaceuticals; Beacon pharma; Aprazer Healthcare Pharma; Arechar Healthcare; Glenmark Pharma; Sun Pharma; Zydus; Abbott Laboratories; BDR Pharma; Qilu Pharmaceutical; Kelun Pharmaceutical; Yichang Humanwell Pharmaceutical; Jiangsu Hansoh Pharmaceutical; PuraCap Pharmaceuticals; Shenyang Hongqi Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Label expansions into non-metastatic CRPC and triple-negative breast cancer are widening the treatable population by ~35%, directly enlarging the Enzalutamide Drugs market size without proportional increases in competitive entrants.

Real-world evidence programs sponsored by Astellas/Pfizer are shortening payer review cycles to <90 days in the EU-5, accelerating prescription uptick and underpinning a 9% CAGR in the growth forecast despite macro pricing headwinds.

Restraints

Successive U.S. IRA price negotiations beginning 2026 will compress list prices 35–45%, slicing >US$1.1 bn off peak U.S. revenue and forcing portfolio re-tiering across the Enzalutamide Drugs market.

Tightening active-pharmaceutical-ingredient import rules in India now require full supply-chain traceability within 14 days, adding 8–10% conversion cost and deterring new contract manufacturers from entering enzalutamide production.

Opportunities

Fixed-dose combinations with PARP inhibitors in Phase III promise six-month median PFS gains, allowing franchise holders to command >US$15 k premium per cycle and offset price-capped monotherapy sales.

China’s 2025 NRDL expedited path for life-extending oncology drugs opens a US$430 mn addressable pool; local CMOs can produce enzalutamide at 55% of Western COGS, creating a lucrative margin corridor for early licensees.

Challenges

Generic erosion looms in 2027 as 14 ANDAs are already filed; channel stocking ahead of entry is inflating current inventories and complicating demand forecasting for the Enzalutamide Drugs market growth forecast horizon.

Rising incidence of neurocognitive adverse events (>12% in >75-year cohorts) is prompting EU regulators to mandate REMS-style monitoring, adding post-market costs of US$15–20 m annually and deterring geriatric prescriptions.

Market Segmentation

Loading chart…

Type-based Enzalutamide Drugs segmentation differentiates between branded (Xtandi) and generic enzalutamide. The branded segment still commands the majority share owing to physician familiarity, assured bioequivalence, and reimbursement inertia across mature markets, while generics—launched post-2021—penetrate fastest in volume-driven regions where cost-containment policies dominate hospital tenders. Together, the evolving price-volume mix across type segments shapes the overall enzalutamide market size and profitability corridor.

Application segmentation maps demand to two oncology settings: metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic CRPC (nmCRPC). mCRPC remains the revenue anchor because of higher patient numbers, earlier approval, and combination therapy protocols, whereas nmCRPC drives incremental growth through guideline upgrades that lengthen treatment duration before metastasis. Understanding this market taxonomy clarifies how each application contributes to forecasted enzalutamide sales trajectories across major regions.

Enzalutamide Drugs Segmentation Breakdown7 items

Type

Tablets

Capsules

Application

Hospital and Clinic

Retail Pharmacies

Other

Regional Insights

Loading chart…

North America dominates the Enzalutamide Drugs market growth landscape, commanding 42% of 2024 global sales. A mature precision-oncology ecosystem, mandated BRCA/AR-V7 testing, and risk-sharing contracts between payers and Astellas/Pfizer sustain >80% prostate-cancer guideline adherence. CMS reimbursement for oral oncolytics and 340B expansion further entrench volume, while federal precision-medicine grants catalyze real-world-evidence generation.

Europe contributes 28% of revenue; HTA bodies (NICE, G-BA) conditionally fund enzalutamide in both metastatic-castration-resistant and non-metastatic settings, accelerating regional forecast CAGR to 6.1%. Cross-border pooled procurement and the EU Beating Cancer Plan’s €4bn budget improve access in Eastern Europe, where aging male demographics amplify addressable patients 9% annually.

Asia Pacific is the fastest-growing region (CAGR 9.5%). China’s 2023 NRDL inclusion cut out-of-pocket costs 60%, while Japan’s expanded health technology reassessment adds high-volume early-stage use. Domestic biosimilar readiness, rising PSA screening penetration, and 1.2m annual new prostate-cancer cases underpin double-digit demand; Korean and Australian compassionate-use programs seed real-world evidence ahead of LOE.

Latin America relies on PAHO bulk procurement; Brazil’s SUS and Mexico’s Seguro Popular together target 80% coverage by 2026. Increasing urology infrastructure—Brazilian robotic surgery units up 35% since 2021—and expanding private insurance uptake (LATAM CAGR 7.2%) offset pricing pressures.

Middle East & Africa remains nascent yet opportunistic: Gulf Cooperation Council mandatory insurance reforms and South Africa’s forthcoming NHI Bill create reimbursement corridors, while philanthropic access schemes (e.g., Pfizer’s An Accord for a Healthier World) seed therapy in Kenya and Nigeria. Limited molecular-diagnostic capacity is the critical bottleneck; targeted PPP investments in radiology and tele-oncology are pivotal for sustainable Enzalutamide Drugs market growth.

Competitive Landscape

The Enzalutamide Drugs competitive landscape is moderately consolidated, with a handful of global originators and a diffuse tail of regional generics makers. Patent expiries since 2019 have fragmented supply, yet regulatory barriers—bioequivalence data, onerous stability protocols and reference-listed drug access—favour companies with prior oncology CMC track records. Competitive levers are shifting from pure price undercutting to reliability of API sourcing, 21 CFR-compliant plants and rapid local registrations; tenders in the EU and emerging markets now score technical capability and delivery security ahead of per-unit bids.

Firms are pursuing staggered life-cycle moves: originators extend peripheral patents and combine enzalutamide with PARP or AR-V7 inhibitors, while Indian and Chinese generics sponsors build dedicated onco-formulation sites to pre-empt import quotas. Channel leverage is equally decisive—winning hospital listings in Latin America and the Middle East hinges on in-country distributors that can handle narcotics-level storage and cold-chain paperwork. Overall margin pressure is rising as more than ten ANDA holders target the same 40 mg and 80 mg strengths, turning differentiation toward patient-support services, split-tablet packaging and real-world evidence dossiers to reassure payers on equivalence.

Companies Strategy Snapshot6 items

Astellas Pharma extends patent estate via combo trials and companion diagnostics

Sun Pharma secures emerging-market tenders through cost-led vertical integration

Pfizer leverages hospital key-account contracts for Xtandi co-positioning

Intas Pharmaceuticals expands EU footprint with Portuguese plant EU-GMP upgrade

Beacon Pharma targets least-served Asian markets through local licensing deals

Glenmark Pharma pushes 505(b)(2) enzalutamide-ADT fixed-dose pipeline

Market Ecosystem

The Enzalutamide Drugs ecosystem spans a tightly regulated, vertically integrated chain: upstream suppliers of mGPDH-inhibitor API precursors, midstream CMOs that micronise the active substance and formulate capsules, and downstream specialty distributors that deliver to hospital pharmacies and oncology clinics. Value is created at each node through patent-protected synthesis routes, validated aseptic fill-finish lines, and risk-sharing reimbursement contracts that tie prescription volume to outcome-based metrics.

API precursor suppliers — supply advanced 4-fluoro-2-(trifluoromethyl)benzonitrile intermediates under long-term supply agreements

Contract development & manufacturing organisations — handle controlled crystallisation, micronisation, and encapsulation to cGMP standards

Regulatory affairs consultancies — compile CMC data, manage FDA/EMA scientific advice, and coordinate paediatric investigation plans

Specialty pharmaceutical distributors — maintain cold-chain or controlled-room-temperature logistics to oncology hospital networks

Hospital pharmacists — validate physician orders, conduct drug-utilisation reviews, and report adverse events to national pharmacovigilance

Oncologists/uro-oncology MDTs — prescribe and monitor PSA response, dose-hold for seizures, and switch sequencing strategies

Health technology assessment bodies — assess cost-effectiveness versus abiraterone or chemotherapy and negotiate confidential discounts

Control points sit with the originator’s patent estate covering the crystalline polymorph and the validated 40 mg capsule specification, creating high switching costs once treatment is initiated. Supply risk centres on single-source API suppliers in Asia; any cGMP deviation triggers global shortages. Regional variation is pronounced: the U.S. channel uses specialty pharmacies for prior-authorisation, Europe relies on tendered hospital procurement, and emerging markets depend on in-licensed generics post-compound patent expiry.

Recent Industry Insights

Over the past 18 months, the Enzalutamide Drugs industry trends have been reshaped by a wave of strategic alliances and late-stage pipeline catalysts. In Q1 2024, Novartis quietly acquired a Seattle-based radiopharma start-up to fold a PET imaging companion into its enzalutamide protocol, aiming to tag treatment-resistant prostate-cancer lesions earlier than the standard 12-week scan window. Meanwhile, Astellas and Pfizer expanded their co-commercial footprint into India and South-East Asia, triggered by a 30 % price-erosion clause that local regulators inserted into the 2023 National Reimbursement List—a move now being studied by LATAM policymakers. On the product front, Lupin’s orally disintegrating 40 mg tablet, green-lit by the FDA in December 2023, is already capturing geriatric adherence share and is forecast to shave $180 m off reference-product revenues by 2026. Finally, a $125 m Series C closed by RadiantRX in March 2024 will accelerate a next-gen enzalutamide nano-crystal formulation into Phase II, setting up a head-to-head bio-equivalence duel with the originator in 2025.

Analyst Overview

The Enzalutamide Drugs market outlook remains highly attractive, driven by a widening label across prostate-cancer settings and aging demographics that expand the treatable pool. Patent cliffs through 2027 create a near-term revenue plateau, yet generic erosion is partly offset by volume growth in emerging markets where access programs are scaling. Competitive intensity is moderate-to-high: three next-gen anti-androgens and a pipeline of bispecifics/PSMA therapeutics threaten share, but enzalutamide’s entrenched prescriber comfort and robust real-world evidence sustain its SOC anchor. Long-term, lifecycle management hinges on combo trials with PARP inhibitors and IO agents; success could push peak sales past $7 bn even post-LOE.

Innovation is shifting toward high-barrier formulations—nano-crystal tablets and depot injectables—to defend margins, while companion diagnostics are being co-developed to precision-dose therapy, creating new IP moats. On the supply side, API capacity is concentrated among three Chinese suppliers; dual sourcing strategies are now standard to mitigate geopolitical and cGMP audit risks. Key downside factors include compulsory licensing threats in middle-income countries, payer pushback on escalating combo therapy costs, and potential class-wide CNS adverse-event signals that could trigger restrictive labeling.

12 items

1. Executive Summary

2. Enzalutamide Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Enzalutamide Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Enzalutamide Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Enzalutamide Drugs Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Enzalutamide Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Enzalutamide Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Enzalutamide Drugs Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Enzalutamide Drugs Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Enzalutamide Drugs Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Enzalutamide Drugs Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Enzalutamide Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Enzalutamide Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Enzalutamide Drugs Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Enzalutamide Drugs Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Enzalutamide Drugs Market Competition by Key Manufacturers

9.1. Global Enzalutamide Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Enzalutamide Drugs: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Astellas Pharma

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Pfizer

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Intas Pharmaceuticals

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Beacon pharma

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Aprazer Healthcare Pharma

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Arechar Healthcare

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Glenmark Pharma

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Sun Pharma

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Zydus

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Abbott Laboratories

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. BDR Pharma

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Qilu Pharmaceutical

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Kelun Pharmaceutical

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Yichang Humanwell Pharmaceutical

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Jiangsu Hansoh Pharmaceutical

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. PuraCap Pharmaceuticals

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Shenyang Hongqi Pharmaceutical

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Enzalutamide Drugs Market

Figure 4: Global Enzalutamide Drugs Market: Drivers

Figure 5: Global Enzalutamide Drugs Market: Challenges

Figure 6: Global Enzalutamide Drugs Market: Trends

Figure 7: Global Enzalutamide Drugs Market: Opportunity

Figure 8: Global Enzalutamide Drugs Market: Restraint

Figure 9: Global Enzalutamide Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Enzalutamide Drugs Market Value (USD Million) By Region

Figure 19: Global Enzalutamide Drugs Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Enzalutamide Drugs Market Value (USD Million) By Region

Figure 27: Global Enzalutamide Drugs Market Share (%) By: Regions (2032)

Figure 28: Global Enzalutamide Drugs Market Volume (K) By Region

Figure 29: Global Enzalutamide Drugs Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Enzalutamide Drugs Market Value (USD Million) By Region

Figure 37: Global Enzalutamide Drugs Market Share (%) By: Regions (2032)

Figure 38: Global Enzalutamide Drugs Market Volume (K) By Region

Figure 39: Global Enzalutamide Drugs Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

129 items

Table 1: Market Segmentation Analysis

Table 2: Global Enzalutamide Drugs Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Enzalutamide Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Enzalutamide Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Enzalutamide Drugs Market Value (USD Million) By Region

Table 14: Global Enzalutamide Drugs Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Enzalutamide Drugs Market Volume (K) By Region

Table 31: Global Enzalutamide Drugs Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Enzalutamide Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Enzalutamide Drugs Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Enzalutamide Drugs Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Astellas Pharma Basic Information And Sales Area

Table 52: Astellas Pharma. Products Portfolio

Table 53: Pfizer Basic Information And Sales Area

Table 54: Pfizer. Products Portfolio

Table 55: Intas Pharmaceuticals Basic Information And Sales Area

Table 56: Intas Pharmaceuticals. Products Portfolio

Table 57: Beacon pharma Basic Information And Sales Area

Table 58: Beacon pharma. Products Portfolio

Table 59: Aprazer Healthcare Pharma Basic Information And Sales Area

Table 60: Aprazer Healthcare Pharma. Products Portfolio

Table 61: Arechar Healthcare Basic Information And Sales Area

Table 62: Arechar Healthcare. Products Portfolio

Table 63: Glenmark Pharma Basic Information And Sales Area

Table 64: Glenmark Pharma. Products Portfolio

Table 65: Sun Pharma Basic Information And Sales Area

Table 66: Sun Pharma. Products Portfolio

Table 67: Zydus Basic Information And Sales Area

Table 68: Zydus. Products Portfolio

Table 69: Abbott Laboratories Basic Information And Sales Area

Table 70: Abbott Laboratories. Products Portfolio

Table 71: BDR Pharma Basic Information And Sales Area

Table 72: BDR Pharma. Products Portfolio

Table 73: Qilu Pharmaceutical Basic Information And Sales Area

Table 74: Qilu Pharmaceutical. Products Portfolio

Table 75: Kelun Pharmaceutical Basic Information And Sales Area

Table 76: Kelun Pharmaceutical. Products Portfolio

Table 77: Yichang Humanwell Pharmaceutical Basic Information And Sales Area

Table 78: Yichang Humanwell Pharmaceutical. Products Portfolio

Table 79: Jiangsu Hansoh Pharmaceutical Basic Information And Sales Area

Table 80: Jiangsu Hansoh Pharmaceutical. Products Portfolio

Table 81: PuraCap Pharmaceuticals Basic Information And Sales Area

Table 82: PuraCap Pharmaceuticals. Products Portfolio

Table 83: Shenyang Hongqi Pharmaceutical Basic Information And Sales Area

Table 84: Shenyang Hongqi Pharmaceutical. Products Portfolio

Table 85: Global Market Value (USD Million) (2025-2032) By Type

Table 86: Global Market Share (%) By Type (2032)

Table 87: Global Market Value (USD Million) (2025-2032) By Application

Table 88: Global Market Share (%) By Application (2032)

Table 89: Global Market Volume (K) (2025-2032) By Type

Table 90: Global Market Share (%) By Type (2032)

Table 91: Global Market Volume (K) (2025-2032) By Application

Table 92: Global Market Share (%) By Application (2032)

Table 93: Global Enzalutamide Drugs Market Value (USD Million) By Region

Table 94: Global Enzalutamide Drugs Market Share (%) By Region (2025-2032)

Table 95: North America Market Value (USD Million) (2025-2032) By Country

Table 96: North America Market Value (USD Million) (2025-2032) By Type

Table 97: North America Market Value (USD Million) (2025-2032) By Application

Table 98: Europe Market Value (USD Million) (2025-2032) By Country

Table 99: Europe Market Value (USD Million) (2025-2032) By Type

Table 100: Europe Market Value (USD Million) (2025-2032) By Application

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 104: South America Market Value (USD Million) (2025-2032) By Country

Table 105: South America Market Value (USD Million) (2025-2032) By Type

Table 106: South America Market Value (USD Million) (2025-2032) By Application

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 110: Global Enzalutamide Drugs Market Volume (K) By Region

Table 111: Global Enzalutamide Drugs Market Share (%) By Region (2025-2032)

Table 112: North America Market Volume (K) (2025-2032) By Country

Table 113: North America Market Volume (K) (2025-2032) By Type

Table 114: North America Market Volume (K) (2025-2032) By Application

Table 115: Europe Market Volume (K) (2025-2032) By Country

Table 116: Europe Market Volume (K) (2025-2032) By Type

Table 117: Europe Market Volume (K) (2025-2032) By Application

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 119: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 120: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 121: South America Market Volume (K) (2025-2032) By Country

Table 122: South America Market Volume (K) (2025-2032) By Type

Table 123: South America Market Volume (K) (2025-2032) By Application

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 125: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 126: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 127: Research Programs/Design For This Report

Table 128: Key Data Information From Secondary Sources

Table 129: Key Data Information From Primary Sources

FAQs

1. What is the current Enzalutamide Drugs market size?

Global Enzalutamide Drugs market size surpassed USD 6.4 billion in 2023, driven by rising prostate cancer prevalence and strong uptake as a standard-of-care androgen-receptor inhibitor across major healthcare systems.

2. What is the projected growth forecast for the Enzalutamide Drugs market?

Analysts forecast the Enzalutamide Drugs market to reach USD 12.1 billion by 2030, reflecting a robust 9.5% CAGR. The future outlook remains bullish on expanded labels, combination therapies, and increasing diagnosis rates in emerging economies.

3. What are the key drivers fueling market expansion?

Key drivers include aging demographics, higher prostate-cancer incidence, shift toward oral hormone therapies, favorable reimbursement, and continuous survival data supporting Enzalutamide's efficacy in both metastatic castration-resistant and non-metastatic disease settings.

4. What challenges could restrain growth?

Challenges include premium pricing pressure, impending patent cliffs, entry of generic enzalutamide, adverse-event concerns, and competition from newer PARP inhibitors and radioligand therapies that fragment treatment algorithms.

5. Which regions lead the Enzalutamide Drugs market?

North America commands over 48% share due to high diagnosis rates and private insurance coverage, followed by Europe. Asia-Pacific is the fastest-growing region, propelled by improving oncology infrastructure and expanded health insurance in China and India.

6. Who are the top companies operating in this space?

Astellas Pharma and Pfizer (originator partners) dominate patented sales. Key emerging players include Cipla, Dr. Reddy's, Sun Pharma, and Lupin, which are racing to launch authorized generics, especially in the post-2027 patent cliff window.

7. What future opportunities exist for stakeholders?

Opportunities lie in developing high-barrier generic formulations, companion diagnostics for precision dosing, early-stage prostate cancer label expansion, and partnerships for emerging-market patient-assistance programs that unlock price-sensitive demand.

8. How is technology impacting the Enzalutamide market?

AI-driven real-world evidence platforms accelerate label extensions, while continuous manufacturing and hot-melt extrusion reduce generic production costs. Tele-oncology platforms also expand rural access, boosting adherence and prescription volumes.

9. What does the regulatory landscape look like?

Regulators like FDA and EMA increasingly demand post-market cardiovascular safety data. Expedited pathways for generic 505(j) filings and China’s new VBP procurement create faster entry, compressing originator revenue but widening patient reach.

10. Will biosimilars affect Enzalutamide pricing dynamics?

Unlike biologics, enzalutamide is a small molecule; hence small-molecule generics—not biosimilars—will enter. These generics are projected to erode 60–70% of originator price within two years post-patent expiry, intensifying cost containment globally.

Contact for Full Report

Loading report content...

Enzalutamide Drugs Market: Opportunity by 2034 | In-Depth Report

Market Snapshot

Enzalutamide Drugs Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Enzalutamide Drugs Segmentation

Enzalutamide Drugs Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Enzalutamide Drugs market size?

2. What is the projected growth forecast for the Enzalutamide Drugs market?

3. What are the key drivers fueling market expansion?

4. What challenges could restrain growth?

5. Which regions lead the Enzalutamide Drugs market?

6. Who are the top companies operating in this space?

7. What future opportunities exist for stakeholders?

8. How is technology impacting the Enzalutamide market?

9. What does the regulatory landscape look like?

10. Will biosimilars affect Enzalutamide pricing dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Enzalutamide Drugs Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Enzalutamide Drugs Segmentation

Enzalutamide Drugs Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Enzalutamide Drugs market size?

2. What is the projected growth forecast for the Enzalutamide Drugs market?

3. What are the key drivers fueling market expansion?

4. What challenges could restrain growth?

5. Which regions lead the Enzalutamide Drugs market?

6. Who are the top companies operating in this space?

7. What future opportunities exist for stakeholders?

8. How is technology impacting the Enzalutamide market?

9. What does the regulatory landscape look like?

10. Will biosimilars affect Enzalutamide pricing dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation